Publications

(1)Miyamura, K., Kojima, S., Takeyama, K., Matsushita, T., Fukuda, M., Horibe, K., Minami, S., Morishima, Y., Matsuyama, K., & Kodera, Y. Use of cyclophosphamide and total lymphoid irradiation combined with cyclosporine in bone marrow transplantation for transfused severe aplastic anemia. Bone Marrow Transplantation 3, 457-461, 1988

(2)Kojima, S., Fukuda, M., Horibe, K., Matsuyama, K., Takeyama, K., Matsushita, T., Miyamura, K., Kimura, Y., Minami, S. & Kodera, Y.: Comparison between bone marrow transplantation and immuno-suppressive therapy in treatment of patients younger than 20 years with severe aplastic anemia. Acta. Haematol. Jpn. 51, 28-35, 1988.

(3)Matsushita, T., Tanimoto, M., Yamamoto, K., Sugiura, I., Hamaguchi, M., Takamatsu, J., Kamiya, T., Saito, H., DNA sequence analysis of three inhibitor-positive hemophilia B patients without gross gene deletion. Identification of four novel mutations in factor IX gene. J Lab Clin Med. 116, 492-497, 1990.

(4)Minami, H., Matsushita, T., Sugihara, T., Kodera, Y., Sakai, S. & Shimokata, K. Cytomegalovirus-induced gastritis in a bone marrow transplant patient. Jpn. J. Med. 29, 433-435, 1990

(5)Saito, H., Matsushita, T., Sugiura, I. & Tanimoto, M. (1991). Genetic diagnosis of congenital coagulopathies. In K. Tanaka (Eds.), Recent advances in Thrombosis and Fibrinolysis (pp. 261-275). Tokyo: Academic Press, Inc.

(6)Hamaguchi, M., Tanimoto, M., Matsushita, T., Yamamoto, K., Sugiura, I., Takamatsu, J., Ogata, T., Kamiya, T. & Saito H. Three distinct point mutations in the factor IX gene of three CRM+ hemophilia B patients (Factor IX BMNagoya 2, B+ Nagoya 3 and 4). Thromb. Haemost. 65, 514-520, 1991

(7)Yamamoto, K., Tanimoto, M., Matsushita, T., Kagami, K., Sugiura, I., Hamaguchi, M., Takamatsu, J. & Saito, H. Genotype establishments for protein C deficiency by use of a DNA polymorphism in the gene. Blood 77, 2633-2636, 1991

(8)Matsushita, T., Tanimoto, M., Yamamoto, K., Sugiura, I., Takamatsu, J., Kamiya, T. & Saito H. Direct carrier detection in hemophilia B kindreds: Use of modified primers (mutagenic primers) for enzymatic amplification of the factor IX gene. Thromb. Res 63, 355-361,1991

(9)Matsushita, T., Takamatsu, J., Kagami, K., Takahashi, I., Sugiura, I., Hamaguchi, M., Kamiya, T. & Saito, H. A female hemophilia A combined with hereditary coagulation factor XII deficiency: a case report. Am. J. Hematol, 39, 137-141, 1991

(10)Yamamoto, K., Matsushita, T., Sugiura, I., Takamatsu, J., Iwasaki, E., Wada, H., Deguchi, K, Shirakawa, S., & Saito, H. Homozygous protein C deficiency: identification of a novel missense mutation that causes impaired secretion of the mutant protein C. J. Lab. Clin. Med. 119, 682-689, 1991.

(11)Suzuki, T., Yamauchi, K., Matsushita, T., Furumachi, T., Furui, H., Tsuzuki, J. & Saito, H.: Elevation of factor VII activity and mass in coronary artery disease of varying severity. Clin. Cardiol. 14, 731-736, 1991.

(12)Sugiura, I., Matsushita, T., Tanimoto, M., Takahashi, I., Yamazaki, T., Yamamoto, K., Takamatsu, J., Kamiya, T. & Saito, H.: Three distinct candidate point mutatations of the von Willebrand factor gene in four patients with type IIA von Willebrand disease. Thromb. Haemost. 67, 612-617, 1992.

(13)Yamamoto, K., Tanimoto, M., Emi, N., Matsushita, T., Takamatsu, J. & Saito, H.: Impaired secretion of the elongated mutant of protein C (protein C-Nagoya). Molecular and celluler basis for hereditary protein C deficiency. J. Clin. Invest. 90, 2439-2446, 1992.

(14)Matsushita, T., Emi, N., Takahashi, I., Takamatsu, J. & Saito, H.: Construction and its expression of a new retroviral vector containing a human blood coagulation factor IX cDNA. Thromb. Res. 69, 387-393, 1993.

(15)Yamazaki, T., Sugiura, I., Matsushita, T., Kojima, T., Kagami, K., Takamtsu, J. & Saito, H.: A phenotypically neutral dimorphism of protein S: the substitution of Lys155 by Glu in the second EGF domain predicted by an A to G base exchange in the gene. Thromb. Res 70, 395-403, 1993.

(16)Matsushita, T., Kojima, T., Emi, N., Takahashi, I. & Saito, H.: Impaired human tissue factor-mediated activity in blood clotting factor VIINagoya (Arg304 _ Trp). Evidence that a region in the catalytic domain of factor VII is important for the association with tissue factor). J. Biol. Chem. 269, 7355-7363, 1994.

(17)Matsushita, T., Dong, Z. & Sadler, J. E.: von Willebrand's factor and von Willebrand's diesease. (review) Current Opinion in Hematology 1, 362-368, 1994.

(18)Sadler, J. E., Matsushita, T., Dong, Z., Tuley, E. & Westfield, L. A.: Molecular mechanism and classification of von Willebrand disease. Thromb. & Haemost. 74, 161-166, 1995.

(19)Matsushita, T. & Sadler, J. E.: Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von willebrand factor. J. Biol. Chem. 270, 13406-13414, 1995.

(20)Toyozumi, H., Kojima, T., Matsushita, T., Hamaguchi, M., Tanimoto, M. & Saito, H.: Diagnosis of hemophilia B carriers using two novel dinucleotide polymorphisms and Hha I RFLP of the factor IX gene in Japanese subjects. Thromb. & Haemost. 74, 1009-14, 1995.

(21)Eikenboom, J. C. J., Matsushita, T., Reitsma, P. H., Tuley, E. A., Castman, G., Bri_t, E., and Sadler, J. E.: Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood 88. 2433-2441, 1996.

(22)Shimizu, A., Sugiura, I., Matsushita, T., Kojima, T., Hirai, M. & Saito, H.: Identification of the five hydrophilic residues (Lys-217, Lys-218, Arg- 359, His-360, and Arg-513) essential for the structure and activity of vitamin K-dependent carboxylase. Biochem Biophys Res Commun 251, 22-6, 1998.

(23)Nichols, W. C., Terry, V. H., Wheatley, M. A., Yang, A., Zivelin, A., Ciavarella, N., Stefanile, C., Matsushita, T., Saito, H., de Bosch, N. B., Ruiz-Saez, A., Torres, A., Thompson, A. R., Feinstein, D. I., White, G. C., Negrier, C., Vinciguerra, C., Aktan, M., Kaufman, R. J., Ginsburg, D. & Seligsohn, U.: ERGIC-53 Gene Structure and Mutation Analysis in 19 Combined Factors V and VIII Deficiency Families. Blood 93, 2261-2266, 1999.

Abstract of International Meetings

(1)Matsushita, T., Tanimoto, M., Sugiura, I., Hamaguchi, M., Takamatsu, J. & Saito, H. Absence of enzymatically amplified HIV-1 proviral sequence in HIV-1 seronegative immuno-deficient hemophiliac patient. In the third meeting of AIDS study group in Japan, Matsue, Japan, 1989.

(2)Matsushita, T., Tanimoto, M., Yamamoto, K., Sugiura, I., Hamaguchi, M., Takamatsu, J. & Saito, H.:Nucleotide sequence analysis of hemophilia B with the inhibitor phenotype. In the 31th annual meeting of American Society of Hematology, Atlanta, GA, 1989

(3)Matsushita, T, Hamaguchi, M.,. Tanimoto, M,. Takamatsu, J. and Saito, H. Molecular pathology of mutant factor IX gene. In the tenth Senri Seminar, "Cellular and molecular pathways of thrombosis formation", Osaka, Japan, 1990

(4)Matsushita, T. DNA analysis of hemophilia A and B. The 7th congress, Asian Pacific division of International Society of Haematology, Hong Kong, 1991.

(5)Matsushita, T., Emi, N., Takamatsu, J. & Saito, H. Identification and in vitro expression analysis of a single amino acid substitution in blood clotting factor VIINagoya(Arg-304_Trp). In the 33th annual meeting of American Society of Hematology, Denver, CO, 1991

(6)Matsushita, T. & Sadler, J. E. Alanine scanning mutagenesis of the A1 domain of human von Willebrand factor identifies amino acid residues essential for binding to glycoprotein Ib. In the 36th annual meeting of American Society of Hematology, Nashville, TN, 1994.

(7)Matsushita, T., Sun, H. & Sadler, J. E. Identification of amino acid residues essential for human von Willebrand factor binding to heparin. In the 37th annual meeting of American Society of Hematology, Seattle, WA, 1995.

Tadashi Matsushita

Last modified： 99.11.21
Copyright preserved